

Michigan MEDICATION SECTION ALBUTEROL

Initial Date: 07/19/23 Revised Date:

Section: 9-12R

Albuterol

Pharmacological Category: Beta-2 Agonist, Bronchodilator

Routes: Nebulized

Indications:

1. Bronchospasm (wheezing)

2. Known or suspected hyperkalemia resulting from a crush injury.

Expected effects:

1. Bronchodilation

2. Decreased respiratory work/effort

Dosing: RESPIRATORY DISTRESS (Adult) PEDIATRIC RESPIRATORY DISTRESS ANAPHYLAXIS/ALLERGIC REACTION PULMONARY EDEMA/CARDIOGENIC SHOCK

Indication: Respiratory distress with wheezing

Adults administer:

1. Albuterol 2.5 mg/3mL NS nebulized

Pediatrics administer: Albuterol dosage is not weight/age based

1. Albuterol 2.5 mg/3mL NS nebulized (Albuterol dosage is not weight/age based)

Dosing: GENERAL CRUSH INJURY

Indication: Suspected hyperkalemia due to crush injury

Adults administer:

Albuterol 2.5 mg/3mL NS nebulized to a maximum dose of 20 mg

Pediatrics administer:

- 1. According to MI MEDIC cards
- 2. If MI MEDIC cards are not available administer Albuterol 2.5 mg/3mL NS nebulized to a maximum dose of 20 mg

Note: A single responding unit is not expected to carry 20 mg of albuterol for treatment of up to 20 mg in Crush Injury protocol. Dosage is a maximum if other resources (i.e., Haz Mat drug box, second drug box) are available.

Used in the Following Protocols

Anaphylaxis/Allergic Reaction (Section 1 General Treatment)

General Crush Injury (Section 2 Trauma and Environmental)

Respiratory Distress (Section 3 Adult Treatment)

Pediatric Respiratory Distress, Failure or Arrest (Section 4 Obstetrics and Pediatrics)

Pulmonary Edema/Cardiogenic Shock (Section 5 Adult Cardiac)

MCA Name: HEMS, Inc. (WW/DR) MCA Board Approval Date: 2/8/2024 MCA Implementation Date: 3/1/2024

MDHHS Approval: 7/19/23 MDHHS Reviewed 2023 Page 1 of 1